Gilead Sciences (GILD) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM EDTUBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results but maintained a Buy rating.
Goddman commented, "We have lowered our HCV sales estimates to reflect lower ASPs (higher rebates to defend share from Merck's... More
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM EDTBMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following the HCV miss. The firm maintained a Market Perform rating, saying it increases the need for pipeline.
Somaiya commented, "Gilead reported 1Q16 EPS... More
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $135 on Gilead Sciences (NASDAQ: GILD) despite a top-line miss driven by weaker U.S. Hep C sales.
Skorney commented, "U.S. Hep C sales came in several hundred million dollars short of expectations.... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM EDTMaxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Jason Kolbert highlighted:
Gilead reported quarterly results with total top-line revenues of $7.6B missing consensus of $7.7B by a hair. Non-GAAP quarterly net income was $4.3B or $3.03 per diluted share. The company ended the period with $21.3B in cash and $22B in debt.HCV revenues continue to drive Gilead but tough comps, the laws of growth (for big numbers), and... MoreGilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM EDTLeerink Partners analyst Geoffrey Porges trimmed his price target on Gilead Sciences (NASDAQ: GILD) to $123.00 (from $127.00) following disappointing Q1 results but maintained an Outperform rating.
Porges commented, "The weakness came in the HCV products, where revenue slid in the US market in the face of... More
